CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

Abstract We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibo...

Full description

Bibliographic Details
Main Authors: Jun Li, Tao Huang, Jun Hua, Qiong Wang, Yang Su, Ping Chen, Scott Bidlingmaier, Allan Li, Zhongqiu Xie, Anil P. Bidkar, Sui Shen, Weibin Shi, Youngho Seo, Robert R. Flavell, Daniel Gioeli, Robert Dreicer, Hui Li, Bin Liu, Jiang He
Format: Article
Language:English
Published: BMC 2023-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
CD46 epitope
Human monoclonal antibody
Targeted alpha therapy
212Pb
Radioimmunotherapy
Prostate cancer
Online Access:https://doi.org/10.1186/s13046-023-02636-x

Internet

https://doi.org/10.1186/s13046-023-02636-x

Similar Items